Foamix to Present Corporate Overview at Jefferies Autumn 2015 Global Healthcare Conference in London

REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 11, 2015 (GLOBE NEWSWIRE) — Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that Dr. Dov Tamarkin, CEO, will provide a corporate overview and business update at the Jefferies Autumn 2015 Global Healthcare Conference in London.

Presentation Details:
Title:Jefferies Autumn 2015 Global Healthcare Conference 
Date:Wednesday, November 18
Time:5:20 pm GMT
Location:The May Fair Hotel, London 

About Foamix Pharmaceuticals Ltd.

Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne and other skin conditions. Foamix Pharmaceuticals’ lead product candidate FMX101 for moderate-to-severe acne is a novel topical foam formulation of the antibiotic minocycline. Foamix Pharmaceuticals also has early-stage stable foam formulations of various drugs for the treatment of common dermatological indications.

CONTACT: Ilan Hadar, CFO
         Foamix Pharmaceuticals Ltd.
         +972-8-9316233
         ilan.hadar@foamixpharma.com
         
         US Investor Relations
         Michael Rice
         LifeSci Advisors, LLC
         646-597-6979
         mrice@lifesciadvisors.com

Ads